Omeros (OMER) Interest & Investment Income (2010 - 2026)
Omeros (OMER) posted Interest & Investment Income of $1.5 million for Q1 2026, up 32.05% sequentially from $1.1 million in Q4 2025, and up 31.34% YoY from $1.1 million in Q1 2025.
Omeros (OMER) Interest & Investment Income (2010 - 2026) Analysis & Trends
Omeros has reported Interest & Investment Income for 11 years, with the latest figure at $1.5 million in Q1 2026.
- Quarterly Interest & Investment Income rose 31.34% year-over-year to $1.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.4 million (down 50.53% YoY) and the FY2025 annual result came in at $4.1 million, down 63.7% from the prior year.
- Interest & Investment Income improved to $1.5 million in Q1 2026 per OMER's latest filing, from $1.1 million in the prior quarter.
- Over five years, Interest & Investment Income peaked at $4.5 million in Q2 2023 and troughed at $493000.0 in Q1 2022.
- A 5-year average of $2.2 million and a median of $2.0 million in 2022 frame the typical range for Interest & Investment Income.
- The sharpest annual moves came in 2023 and 2025: Interest & Investment Income surged 703.85% in 2023, then plunged 73.74% in 2025.
- Over 5 years, Interest & Investment Income stood at $2.0 million in 2022, then jumped by 72.05% to $3.4 million in 2023, then sank by 33.6% to $2.3 million in 2024, then sank by 50.94% to $1.1 million in 2025, then soared by 32.05% to $1.5 million in 2026.
- According to Business Quant data, Interest & Investment Income over the past three periods registered $1.5 million, $1.1 million, and $616000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 48.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 35.58 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 27.90 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 5.13 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 28.14 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Omeros | 1.24 Bn | 1.24 Bn | 27.73 Mn | 4.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.63 Mn |
| Mar 31, 2026 | 1.48 Mn |
| Dec 31, 2025 | 1.12 Mn |
| Sep 30, 2025 | 616,000.00 |
| Jun 30, 2025 | 1.24 Mn |
| Mar 31, 2025 | 1.12 Mn |
| Dec 31, 2024 | 2.28 Mn |
| Sep 30, 2024 | 2.35 Mn |
| Jun 30, 2024 | 3.25 Mn |
| Mar 31, 2024 | 3.42 Mn |
| Dec 31, 2023 | 3.43 Mn |
| Sep 30, 2023 | 4.41 Mn |
| Jun 30, 2023 | 4.54 Mn |
| Mar 31, 2023 | 3.96 Mn |
| Dec 31, 2022 | 1.99 Mn |
| Sep 30, 2022 | 906,000.00 |
| Jun 30, 2022 | 670,000.00 |
| Mar 31, 2022 | 493,000.00 |
| Dec 31, 2021 | 528,000.00 |
| Sep 30, 2021 | 461,000.00 |